Holen Sie sich die Stockscreener-App
6.32
0.64%
0.04
Vorhandelsmarkt:
6.32
Schlusskurs vom Vortag:
$6.28
Offen:
$6.27
24-Stunden-Volumen:
427.32K
Relative Volume:
0.77
Marktkapitalisierung:
$205.54M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-29.25M
KGV:
-5.3288
EPS:
-1.186
Netto-Cashflow:
$-22.80M
1W Leistung:
-2.17%
1M Leistung:
-24.13%
6M Leistung:
+6.40%
1J Leistung:
+29.24%
1-Tages-Spanne:
$6.21
$6.5773
1-Wochen-Bereich:
$5.95
$6.5773
52-Wochen-Spanne:
$1.73
$11.41
Sagimet Biosciences Inc Stock (SGMT) Company Profile
Firmenname
Sagimet Biosciences Inc
Sektor
Branche
Telefon
(650) 561-8600
Adresse
155 BOVET RD., SUITE 303, SAN MATEO
Vergleichen Sie SGMT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SGMT
Sagimet Biosciences Inc
|
6.32 | 204.24M | 0 | -29.25M | -22.80M | -1.186 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-11 | Eingeleitet | Wedbush | Outperform |
| 2025-08-07 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-07-24 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-12-06 | Eingeleitet | Oppenheimer | Outperform |
| 2024-11-12 | Eingeleitet | UBS | Buy |
| 2024-06-28 | Herabstufung | Goldman | Buy → Neutral |
| 2024-05-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-03-25 | Eingeleitet | Leerink Partners | Outperform |
| 2023-08-08 | Eingeleitet | Goldman | Buy |
| 2023-08-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-08-08 | Eingeleitet | Piper Sandler | Overweight |
| 2023-08-08 | Eingeleitet | TD Cowen | Outperform |
Alle ansehen
Sagimet Biosciences Inc Aktie (SGMT) Neueste Nachrichten
What drives Sagimet Biosciences Inc stock priceStock Split Announcements & High Yield Portfolio Picks - earlytimes.in
Sagimet Biosciences announces China’s NMPA accepted NDA for denifanstat - TipRanks
Sagimet's license partner Ascletis announced acceptance of new drug application for Denifanstat - marketscreener.com
Sagimet Biosciences Licenses Denifanstat for Acne Treatment to Ascletis Pharma as NMPA Accepts NDA in China - Quiver Quantitative
Sagimet’s License Partner Ascletis Announced Acceptance of - GlobeNewswire
Sagimet Biosciences (Nasdaq: SGMT) sees China partner’s acne drug NDA accepted by NMPA - Stock Titan
Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
A significant driver of top-line growth: Sagimet Biosciences Inc (SGMT) - Setenews
Is Sagimet Biosciences Inc. (0O2) stock worth holding before Fed meetingQuarterly Risk Review & Daily Risk Controlled Trade Plans - Newser
Is Sagimet Biosciences Inc. (0O2) stock prepared for digital transitionWeekly Trade Analysis & Low Risk High Reward Trade Ideas - Newser
How Sagimet Biosciences Inc. (0O2) stock trades after earningsTrade Ideas & Verified Technical Trade Signals - Newser
How cyclical is Sagimet Biosciences Inc. (0O2) stock compared to rivalsJuly 2025 WrapUp & Accurate Trade Setup Notifications - Newser
Is Sagimet Biosciences Inc. (0O2) stock a buy during volatile markets2025 Biggest Moves & Precise Entry and Exit Recommendations - Newser
Why Sagimet Biosciences Inc. (0O2) stock stays undervaluedCEO Change & Entry Point Strategy Guides - Newser
How resilient is Sagimet Biosciences Inc. stock in market downturnsEarnings Miss & High Return Trade Opportunity Guides - Newser
Will Sagimet Biosciences Inc. stock benefit from commodity prices2025 Market Outlook & Real-Time Market Trend Scan - Newser
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Sagimet Biosciences (NASDAQ:SGMT) Downgraded to “Sell” Rating by Wall Street Zen - Defense World
Sagimet Biosciences (NASDAQ:SGMT) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Sagimet Biosciences executive chairman sells $290k in shares By Investing.com - Investing.com Australia
Insider Selling: Sagimet Biosciences (NASDAQ:SGMT) Chairman Sells 37,688 Shares of Stock - MarketBeat
Insider Sell: George Kemble Sells Shares of Sagimet Biosciences Inc (SGMT) - GuruFocus
Sagimet Biosciences executive chairman sells $290k in shares - Investing.com
Will Sagimet Biosciences Inc. (0O2) stock sustain bullish trend into 2025Weekly Stock Recap & AI Enhanced Market Trend Forecasts - newser.com
Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference - The Manila Times
Sagimet Biosciences Inc. to Participate in 8th Annual Evercore ISI Healthcare Conference on December 2, 2025 - Quiver Quantitative
Why Sagimet Biosciences Inc. (0O2) stock attracts wealthy investorsMarket Risk Summary & Growth Focused Investment Plans - newser.com
Can Sagimet Biosciences Inc. (0O2) stock attract analyst upgradesPortfolio Update Report & Risk Adjusted Swing Trade Ideas - newser.com
What catalysts could drive Sagimet Biosciences Inc. stock higherPortfolio Risk Report & Weekly High Potential Stock Alerts - newser.com
Detecting support and resistance levels for Sagimet Biosciences Inc.July 2025 Outlook & Safe Capital Preservation Plans - newser.com
Sagimet Biosciences Inc (0O2.MU) Stock Price, News, Quote & History - Yahoo! Finance Canada
How sustainable is Sagimet Biosciences Inc. stock dividend payoutJuly 2025 Short Interest & Safe Capital Allocation Plans - newser.com
Identifying reversal signals in Sagimet Biosciences Inc.Rate Cut & Fast Exit and Entry Trade Guides - newser.com
Reversal indicators forming on Sagimet Biosciences Inc. stockWeekly Stock Summary & Consistent Income Trade Recommendations - newser.com
Published on: 2025-11-19 02:00:25 - newser.com
Finanzdaten der Sagimet Biosciences Inc-Aktie (SGMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):